Zu Yuangang, Wu Weiwei, Zhao Xiuhua, Li Yong, Wang Weiguo, Zhong Chen, Zhang Yin, Zhao Xue
Key Laboratory of Forest Plant Ecology, Northeast Forestry University, Ministry of Education, Harbin, Heilongjiang 150040, China.
Key Laboratory of Forest Plant Ecology, Northeast Forestry University, Ministry of Education, Harbin, Heilongjiang 150040, China.
Int J Pharm. 2014 Aug 25;471(1-2):366-76. doi: 10.1016/j.ijpharm.2014.05.049. Epub 2014 Jun 2.
Taxifolin is a kind of flavanonol, whose antioxidant ability is superior to that of ordinary flavonoids compounds owing to its special structure. However, its low bioavailability is a major obstacle for biomedical applications, so the experiment is designed to prepare taxifolin nanoparticles by liquid antisolvent precipitation (LAP) to improve its bioavailability. We selected ethanol as solvent, deionized water as antisolvent, and investigated primarily the type of surfactant and adding amount, drug concentration, volume ratio of antisolvent to solvent, precipitation temperature, dropping speed, stirring speed, stirring time factors affecting drug particles size. Results showed that the poloxamer 188 was selected as the surfactant and the particle size of taxifolin obviously reduced with the increase of the poloxamer 188 concentration, the drug concentration and the dropping speed from 0.08% to 0.45%, from 0.04 g/ml to 0.12 g/ml, from 1 ml/min to 5 ml/min, respectively, when the volume ratio of antisolvent to solvent increased from 2.5 to 20, the particle size of taxifolin first increased and then decreased, the influence of precipitation temperature, stirring speed, stirring time on particle size were not obvious, but along with the increase of mixing time, the drug solution would separate out crystallization. The optimum conditions were: the poloxamer 188 concentration was 0.25%, the drug concentration was 0.08 g/ml, the volume ratio of antisolvent to solvent was 10, the precipitation temperature was 25 °C, the dropping speed was 4 ml/min, the stirring speed was 800 r/min, the stirring time was 5 min. Taxifolin nanosuspension with a MPS of 24.6 nm was obtained under the optimum conditions. For getting taxifolin nanoparticles, the lyophilization method was chosen and correspondingly γ-cyclodextrin was selected as cryoprotectant from γ-cyclodextrin, mannitol, lactose, glucose. Then the properties of raw taxifolin and taxifolin nanoparticles were characterized by scanning electron microscopy (SEM), fourier-transform infrared spectroscopy (FTIR), high performance liquid chromatography-mass spectrometry (LC-MS), X-ray diffraction (XRD), differential scanning calorimetry (DSC), and thermo gravimetric (TG), and the conclusion was drawn that taxifolin nanoparticles can be converted into an amorphous form but its chemical construction cannot been changed. Furthermore, dissolving capability test, 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical-scavenging activity and reducing power assay, solvent residue test were also carried out. The experimental data showed that the solubility and the dissolution rate of taxifolin nanoparticles were about 1.72 times and 3 times of raw taxifolin, the bioavailability of taxifolin nanoparticles increased 7 times compared with raw taxifolin, and the antioxidant capacity of taxifolin nanoparticles was also superior to raw taxifolin. Furthermore, the residual ethanol of the taxifolin nanoparticles was less than the ICH limit for class 3 solvents of 5000 ppm or 0.5% for solvents and could be used for pharmaceutical. These results suggested that taxifolin nanoparticles might have potential value to become a new oral taxifolin formulation with high bioavailability.
紫杉叶素是一种黄烷醇,由于其特殊结构,其抗氧化能力优于普通黄酮类化合物。然而,其低生物利用度是生物医学应用的主要障碍,因此设计实验通过液体反溶剂沉淀法(LAP)制备紫杉叶素纳米颗粒以提高其生物利用度。我们选择乙醇作为溶剂,去离子水作为反溶剂,并主要研究了表面活性剂类型及添加量、药物浓度、反溶剂与溶剂的体积比、沉淀温度、滴速、搅拌速度、搅拌时间等影响药物粒径的因素。结果表明,选择泊洛沙姆188作为表面活性剂,随着泊洛沙姆188浓度从0.08%增加到0.45%、药物浓度从0.04 g/ml增加到0.12 g/ml、滴速从1 ml/min增加到5 ml/min,紫杉叶素的粒径明显减小;当反溶剂与溶剂的体积比从2.5增加到20时,紫杉叶素的粒径先增大后减小;沉淀温度、搅拌速度、搅拌时间对粒径的影响不明显,但随着混合时间的增加,药物溶液会析出结晶。最佳条件为:泊洛沙姆188浓度为0.25%,药物浓度为0.08 g/ml,反溶剂与溶剂的体积比为10,沉淀温度为25℃,滴速为4 ml/min,搅拌速度为800 r/min,搅拌时间为5 min。在最佳条件下获得了平均粒径为24.6 nm的紫杉叶素纳米混悬液。为了得到紫杉叶素纳米颗粒,选择冷冻干燥法,并从γ-环糊精、甘露醇、乳糖、葡萄糖中相应地选择γ-环糊精作为冻干保护剂。然后通过扫描电子显微镜(SEM)、傅里叶变换红外光谱(FTIR)、高效液相色谱-质谱联用(LC-MS)、X射线衍射(XRD)、差示扫描量热法(DSC)和热重分析法(TG)对紫杉叶素原料药和紫杉叶素纳米颗粒的性质进行了表征,得出紫杉叶素纳米颗粒可转变为无定形形式但其化学结构未改变的结论。此外,还进行了溶解能力测试、2,2-二苯基-1-苦基肼基(DPPH)自由基清除活性和还原能力测定、溶剂残留测试。实验数据表明,紫杉叶素纳米颗粒的溶解度和溶出速率分别约为紫杉叶素原料药的1.72倍和3倍,紫杉叶素纳米颗粒的生物利用度比紫杉叶素原料药提高了7倍,且紫杉叶素纳米颗粒的抗氧化能力也优于紫杉叶素原料药。此外,紫杉叶素纳米颗粒的残留乙醇低于国际协调会议(ICH)对3类溶剂5000 ppm或0.5%的限度,可用于制药。这些结果表明,紫杉叶素纳米颗粒可能具有成为一种新型高生物利用度口服紫杉叶素制剂的潜在价值。